News
Hosted on MSN2mon
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mTA-MUC1, the target of gatipotuzumab ... for datopotamab deruxtecan (Dato-DXd), an ADC targeting EGFR-mutated non–small cell lung cancer (NSCLC) developed by Daiichi Sankyo and AstraZeneca.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback